Suppr超能文献

近期药物/分子再利用以管理 COVID-19 的进展。

Recent progress in the repurposing of drugs/molecules for the management of COVID-19.

机构信息

CRF, Mass Spectrometry Laboratory, Kusuma School of Biological Sciences (KSBS), Indian Institute of Technology, Delhi, India.

Department of Medicine, Loyola University Medical Center, Chicago, IL, USA.

出版信息

Expert Rev Anti Infect Ther. 2021 Jul;19(7):889-897. doi: 10.1080/14787210.2021.1860020. Epub 2020 Dec 10.

Abstract

: In the current scenario, COVID-19 is a clinical and public health problem globally. Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) remains the causative agent, emerged in China and continuously spreading across the globe. Until now, no efficient therapeutics have been approved, which combat COVID-19. FDA approved broad-spectrum drugs/molecules could be repurposed against the COVID-19 and are under clinical trials, if the outcome of these trials proves positive, it could be used to manage COVID-19 pandemic.: This article reviews the FDA approved drugs/molecules which could be repurposed in the combination or single to combat the COVID-19.: In this focused review, we suggested the repurposing of the pathogen-centric, host-centric, dual sword (act as pathogen-centric as well as host-centric), and the combinatorial (pathogen and host-centric) drugs against COVID-19 patients. These drugs singly or in combination could be effective for the management of COVID-19.

摘要

在当前情况下,COVID-19 是一个全球性的临床和公共卫生问题。严重急性呼吸综合征冠状病毒 2(SARS-CoV-2)仍然是病原体,它在中国出现,并持续在全球传播。到目前为止,还没有批准任何有效的治疗方法来对抗 COVID-19。美国食品和药物管理局(FDA)批准的广谱药物/分子可以被重新用于对抗 COVID-19,并正在进行临床试验,如果这些试验的结果是阳性的,它可以用于管理 COVID-19 大流行。本文综述了美国食品和药物管理局(FDA)批准的可用于联合或单独对抗 COVID-19 的药物/分子。在本次重点综述中,我们建议针对 COVID-19 患者,重新利用以病原体为中心、以宿主为中心、双剑(既以病原体为中心,也以宿主为中心)和组合(病原体和宿主为中心)药物。这些药物单独或联合使用可能对 COVID-19 的管理有效。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验